Your browser doesn't support javascript.

Biblioteca Virtual em Saúde

Brasil

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

The incidence and risk factors of hepatic veno-occlusive disease after hematopoietic stem cell transplantation in Taiwan.

Lee, Chien-Chang; Chang, Hsiu-Hao; Lu, Meng-Yao; Yang, Yung-Li; Chou, Shu-Wei; Lin, Dong-Tsamn; Jou, Shiann-Tarng; Yao, Ming; Li, Chi-Cheng; Yeh, Su-Peng; Chen, Mei-Hui; Gau, Jyh-Pyng; Li, Sin-Syue; Wang, Po-Nan; Liu, Yi-Chang; Wang, Tso-Fu; Tan, Tran-Der; Lee, Ming-Yang; Yu, Ming-Sun; Wang, Chuan-Cheng; Lin, Shih-Chiang; Chen, Yeu-Chin; Su, Yung-Cheng; Su, Ko-Ying; Lin, Kai-Hsin.
Ann Hematol; 98(3): 745-752, 2019 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-30666432
Hepatic veno-occlusive disease (VOD) is a potentially fatal complication of hematopoietic stem cell transplantation (HSCT). We conducted this study to investigate the incidence and risk factors of hepatic VOD for patients receiving HSCT in Taiwan. We retrospectively analyzed the data from a nationwide registry for patients receiving HSCT, which was collected by the Taiwan Society of Blood and Marrow Transplantation. The data collection period was from 2009 to 2014. A total 2345 patients were reviewed and 39 patients among them were diagnosed as having hepatic VOD. The cumulative incidence of hepatic VOD in the whole cohort of 2345 patients was 1.66%. In multivariate analysis, disease diagnosis of myelodysplastic syndrome, chronic HCV infection, condition regimens of bulsulfan intravenously administered, and antithymocyte immunoglobulin were independent factors to predict higher risk of hepatic VOD. The overall mortality rate for patients with hepatic VOD was 79%. Patients with hepatic VOD had significant worse survival outcomes when compared with those without hepatic VOD (P = 0.00063). In conclusion, although the incidence is low, hepatic VOD remains a serious complication after HSCT in Taiwan. The findings of this study could be the basis for developing prophylactic or early treatment strategies for hepatic VOD.
Selo DaSilva